TFB Advisors LLC Acquires New Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

TFB Advisors LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, Holdings Channel reports. The institutional investor bought 544 shares of the company’s stock, valued at approximately $294,000.

Several other large investors have also recently bought and sold shares of IDXX. Mediolanum International Funds Ltd bought a new stake in IDEXX Laboratories in the first quarter worth $10,092,000. Rehmann Capital Advisory Group increased its stake in shares of IDEXX Laboratories by 3.1% during the first quarter. Rehmann Capital Advisory Group now owns 985 shares of the company’s stock valued at $532,000 after purchasing an additional 30 shares in the last quarter. Commerce Bank raised its stake in IDEXX Laboratories by 0.8% during the first quarter. Commerce Bank now owns 11,634 shares of the company’s stock valued at $6,282,000 after buying an additional 91 shares during the last quarter. GSA Capital Partners LLP purchased a new position in IDEXX Laboratories in the 1st quarter worth about $1,472,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in IDEXX Laboratories by 906.8% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 735 shares of the company’s stock worth $397,000 after purchasing an additional 662 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. Barclays decreased their price target on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, May 2nd. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, Morgan Stanley decreased their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Price Performance

Shares of IDXX stock traded up $5.50 during trading hours on Wednesday, hitting $483.39. The stock had a trading volume of 328,144 shares, compared to its average volume of 467,932. The stock’s 50-day moving average price is $499.62 and its two-hundred day moving average price is $523.27. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock has a market capitalization of $39.92 billion, a price-to-earnings ratio of 46.79, a PEG ratio of 3.95 and a beta of 1.32. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Equities analysts forecast that IDEXX Laboratories, Inc. will post 11.03 EPS for the current year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of IDEXX Laboratories stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.